Argos Therapeutics Inc (ARGS): B.v. Forargos , 10% owner of Argos Therapeutics Inc purchased 1,322,618 shares on Jun 29, 2016. The Insider buying transaction was reported by the company on Jul 1, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.00 per share for a total value of $0.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 16, 2016, Hubert Birner (director) purchased 183,697 shares at $0.00 per share price.On Mar 16, 2016, Deventer Sander Van (director 10% owner) purchased 881,745 shares at $0.00 per share price.Also, On Jan 8, 2016, Jeffrey D Abbey (CEO) purchased 5,000 shares at $2.50 per share price.On Dec 17, 2015, Joan Winterbottom (Chief Human Resources Officer) purchased 250 shares at $1.83 per share price.
Argos Therapeutics Inc: On Wednesday, Jun 29, 2016 heightened volatility was witnessed in Argos Therapeutics Inc which led to swings in the share price. The shares opened for trading at $5.6 and hit $5.6599 on the upside , eventually ending the session at $5.62, with a gain of 2.18% or 0.12 points. The heightened volatility saw the trading volume jump to 1,91,808 shares. The 52-week high of the share price is $13.97 and the company has a market cap of $146 M . The 52-week low of the share price is at $1.61.
Argos Therapeutics Inc. (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003 which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers. The Company is also developing AGS-004 its second Arcelis-based product candidate for the treatment of Human Immunodeficiency Virus (HIV). The Company is conducting a Phase III clinical trial of AGS-003 plus sunitinib/targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA) with the Food and Drug Administration (FDA). The Company has completed three clinical trials of AGS-004. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate personalized immunotherapies.